| Wall Street Analysts Predict a 310.96% Upside in Candel Therapeutics (CADL): Here's What You Should Know |
The mean of analysts' price targets for Candel Therapeutics (CADL) points to a 311% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock. |
zacks.com |
2025-05-16 15:01:14 |
Czytaj oryginał (ang.) |
| Candel Therapeutics posts Q1 profit, eyes 2026 BLA submission for prostate cancer drug |
Candel Therapeutics Inc (NASDAQ:CADL) reported a quarterly profit and said it remains on track to submit a biologics license application (BLA) in late 2026 for its lead cancer therapy, CAN-2409, aimed at treating localized prostate cancer. The clinical-stage biotech posted net income of $7.4 million for the first quarter ended March 31, compared with a net loss of $8.2 million a year earlier, helped by a $15.5 million gain linked to changes in the fair value of its warrant liability. |
proactiveinvestors.com |
2025-05-13 13:03:08 |
Czytaj oryginał (ang.) |
| Candel Therapeutics Reports First Quarter 2025 Financial Results and Recent Corporate Highlights |
NEEDHAM, Mass., May 13, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, announced today financial results for the first quarter ended March 31, 2025, and provided a corporate update. |
globenewswire.com |
2025-05-13 12:05:00 |
Czytaj oryginał (ang.) |
| Candel Therapeutics to Present at Upcoming Investor Conferences |
NEEDHAM, Mass., May 06, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, announced today that management will present and participate in one-on-one meetings with investors at upcoming investor conferences. |
globenewswire.com |
2025-05-06 12:05:00 |
Czytaj oryginał (ang.) |
| Candel Therapeutics Announces Oral Presentation of Positive Phase 3 CAN-2409 Results in Localized Prostate Cancer at ASCO 2025 |
NEEDHAM, Mass., April 23, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced that an abstract was accepted for an oral presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting taking place May 30 to June 3, 2025, in Chicago, IL. The oral presentation will feature data from the Company's phase 3 clinical trial of CAN-2409 in patients with intermediate-to-high risk localized prostate cancer. |
globenewswire.com |
2025-04-23 20:05:00 |
Czytaj oryginał (ang.) |
| Candel Therapeutics reveals new data showing better outcomes for glioma patients using CAN-2409 |
Candel Therapeutics Inc (NASDAQ:CADL) shared promising results from a Phase 1b clinical trial testing its experimental cancer therapy, CAN-2409, in patients with newly diagnosed high-grade glioma—a particularly aggressive form of brain cancer. The study, published in Neuro-Oncology, found that CAN-2409, when combined with the immunotherapy drug nivolumab and standard treatments like surgery, radiation, and chemotherapy, was well tolerated and showed signs of boosting the immune system's response to tumors. |
proactiveinvestors.com |
2025-04-01 13:46:37 |
Czytaj oryginał (ang.) |
| Candel Therapeutics Announces Publication of Phase 1b Clinical Trial Data on the Combination of CAN-2409 and Nivolumab plus Standard of Care in Newly Diagnosed High-Grade Glioma Patients |
Data published in Neuro-Oncology demonstrate promising safety profile and potential survival benefit when combining CAN-2409 and nivolumab with standard of care Data published in Neuro-Oncology demonstrate promising safety profile and potential survival benefit when combining CAN-2409 and nivolumab with standard of care |
globenewswire.com |
2025-04-01 12:01:00 |
Czytaj oryginał (ang.) |
| Candel Therapeutics reports breakthrough data for late-stage lung cancer – ICYMI |
Candel Therapeutics Inc (NASDAQ:CADL) earlier this week shared updated clinical data from a Phase 2a study evaluating its immunotherapy candidate CAN-2409 in patients with advanced non-small cell lung cancer. The company said the study enrolled patients who had exhausted standard treatment options, including chemotherapy and checkpoint inhibitors. |
proactiveinvestors.com |
2025-03-29 11:19:59 |
Czytaj oryginał (ang.) |
| Candel Therapeutics reports positive survival data for CAN-2409 in advanced lung cancer trial |
Candel Therapeutics Inc (NASDAQ:CADL) said on Wednesday that its experimental immunotherapy, CAN-2409, demonstrated prolonged median overall survival in a Phase 2a clinical trial for patients with advanced non-small cell lung cancer (NSCLC) who had not responded to immune checkpoint inhibitors (ICI). Patients receiving CAN-2409 showed a median overall survival of 24.5 months, exceeding historical survival rates for this population, the company said. |
proactiveinvestors.com |
2025-03-26 18:21:44 |
Czytaj oryginał (ang.) |
| Candel Therapeutics Reports Both Prolonged Median Overall Survival and Long Tail of Survival in Phase 2a Clinical Trial of CAN-2409 in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Non-Responsive to Immune Checkpoint Inhibitor (ICI) Treatment |
NEEDHAM, Mass., March 26, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced final survival data from a phase 2a clinical trial of CAN-2409 in patients with stage III/IV NSCLC, inadequately responding to ICI treatment. mOS was 24.5 months in 46 evaluable patients receiving 2 courses of CAN-2409 (per protocol population; cohort 1 and 2) and 21.5 months in evaluable patients from cohort 2 (n=41) that presented with progressive disease at baseline, despite ICI treatment. mOS in patients with progressive disease despite ICI treatment, was 9.8-11.8 months in other studies, including those with standard of care of docetaxel chemotherapy, which has a very poor prognosis, did not exceed 12 months in other published studies.(1, 2 ) This final analysis included extended follow-up data (1 year after the previous data cut) with a median follow up time for the per protocol population of 32.4 months. Data showed a sizable percentage of patients with survival exceeding 24 months, evidence of a long tail of survival, with 37% of patients with progressive disease despite treatment with ICI alive 2 years after CAN-2409 administration. |
globenewswire.com |
2025-03-26 18:05:00 |
Czytaj oryginał (ang.) |
| Bears are Losing Control Over Candel Therapeutics (CADL), Here's Why It's a 'Buy' Now |
Candel Therapeutics (CADL) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term. |
zacks.com |
2025-03-25 12:55:37 |
Czytaj oryginał (ang.) |
| Candel Therapeutics partners with IDEA Pharma on commercialization of lead asset CAN-2409 |
Candel Therapeutics Inc (NASDAQ:CADL) announced that it has partnered with IDEA Pharma to advance the commercialization of its lead immunotherapy candidate CAN-2409. The collaboration follows positive Phase 3 data showing CAN-2409 significantly improved disease-free survival in patients with intermediate-to-high-risk localized prostate cancer. |
proactiveinvestors.com |
2025-03-20 12:04:10 |
Czytaj oryginał (ang.) |
| Candel Therapeutics and IDEA Pharma Announce Strategic Partnership to Advance Path-to-Market Commercialization Efforts for CAN-2409 |
NEEDHAM, Mass., March 20, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, together with IDEA Pharma, a Division of SAI MedPartners (IDEA), a pioneering biopharmaceutical strategy consultancy, today announced a strategic commercial partnership. |
globenewswire.com |
2025-03-20 10:00:00 |
Czytaj oryginał (ang.) |
| Candel Therapeutics appoints cancer immunology expert to research advisory board |
Candel Therapeutics Inc (NASDAQ:CADL) said on Tuesday it has appointed Dr Elizabeth Jaffee to its research advisory board. Jaffee, an internationally recognized expert in cancer immunology and pancreatic cancer, currently serves as the Dana and Albert "Cubby" Broccoli Professor of Oncology and Deputy Director of the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. |
proactiveinvestors.com |
2025-03-18 11:32:57 |
Czytaj oryginał (ang.) |
| Candel Therapeutics Appoints Renowned Pancreatic Cancer Expert, Elizabeth M. Jaffee, M.D. |
NEEDHAM, Mass., March 18, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced the appointment of Elizabeth M. Jaffee, M.D., to the Company's Research Advisory Board (RAB). Dr. Jaffee, an internationally recognized expert in cancer immunology and pancreatic cancer, brings her extensive expertise to the RAB, which is important in light of the Company's focus on borderline resectable pancreatic cancer. |
globenewswire.com |
2025-03-18 10:00:00 |
Czytaj oryginał (ang.) |
| Candel Therapeutics eyes CAN-2409 BLA filing, advances cancer pipeline |
Candel Therapeutics Inc (NASDAQ:CADL) said on Thursday it is preparing to submit a Biologics License Application (BLA) for its lead candidate, CAN-2409, in prostate cancer, as the company pushes forward with late-stage development across multiple cancer indications. CEO Paul Peter Tak said the company enters 2025 “well-resourced with a clear direction,” focusing on regulatory readiness for CAN-2409's potential approval. |
proactiveinvestors.com |
2025-03-13 18:41:34 |
Czytaj oryginał (ang.) |
| Candel Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights |
NEEDHAM, Mass., March 13, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, announced today financial results for the fourth quarter and year ended December 31, 2024, and provided a corporate update. |
globenewswire.com |
2025-03-13 18:15:00 |
Czytaj oryginał (ang.) |
| Candel Therapeutics CEO discusses promising Phase 2 pancreatic cancer trial results - ICYMI |
Candel Therapeutics Inc (NASDAQ:CADL) CEO Dr Paul Peter Tak talked with Proactive about the encouraging results from the phase 2 trial of its investigational medicine CAN-2409 for borderline resectable pancreatic cancer. Dr Tak shared that the median overall survival in the active treatment group reached 31.4 months, compared to just 12.5 months in the control group, showing a clear separation of survival curves. |
proactiveinvestors.com |
2025-02-28 17:49:01 |
Czytaj oryginał (ang.) |
| Candel Therapeutics: I Say Stay The Course Despite The Market's Rebuke Of Positive Pancreatic Data |
Candel Therapeutics' recent phase 2 results in pancreatic cancer showed promising median survival but led to a 20% stock drop due to market skepticism. Despite the drop, I maintain a "Buy" sentiment, emphasizing the significant potential in prostate cancer and the unjustified negative reaction to positive news. CADL's financial health improved with a $92 million share offering, extending their runway to over three years, supporting their ongoing projects. |
seekingalpha.com |
2025-02-25 18:52:12 |
Czytaj oryginał (ang.) |
| Candel Therapeutics reports significant survival benefit for pancreatic cancer therapy |
Candel Therapeutics Inc (NASDAQ:CADL) announced positive final overall survival data from its Phase 2 clinical trial of CAN-2409, an investigational immunotherapy for pancreatic ductal adenocarcinoma (PDAC), showing a significant survival benefit for patients with borderline resectable disease. The trial demonstrated an estimated median overall survival of 31.4 months for patients receiving CAN-2409 in combination with valacyclovir and standard-of-care chemoradiation, compared to just 12.5 months in the control group. |
proactiveinvestors.com |
2025-02-25 11:08:11 |
Czytaj oryginał (ang.) |
| Candel Therapeutics Announces Positive Final Survival Data from Randomized Controlled Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer |
NEEDHAM, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced final overall survival data from the completed randomized controlled phase 2 clinical trial of CAN-2409 plus valacyclovir (prodrug), together with standard of care (SoC) chemoradiation, followed by resection, in patients with borderline resectable PDAC. |
globenewswire.com |
2025-02-25 10:00:00 |
Czytaj oryginał (ang.) |
| Candel Therapeutics: Entering Its Pivotal Year |
Candel Therapeutics' lead candidate CAN-2409 shows promising results in several indications. CAN-2409's Phase 2a pancreatic cancer study could be released this quarter, and its prostate cancer drug could see an FDA submission mid-year. The shorts have melted away, and the ticker is seeing strong price action. |
seekingalpha.com |
2025-02-20 12:45:55 |
Czytaj oryginał (ang.) |
| Candel Therapeutics advancing lead candidate targeting prostate cancer towards FDA submission |
Candel Therapeutics Inc (NASDAQ:CADL) has provided a corporate update, highlighting anticipated milestones for this year building upon significant achievements in 2024. Updated overall survival data from phase 2a trials of its lead candidate CAN-2409 in pancreatic ductal adenocarcinoma (PDAC) and non-small cell lung cancer (NSCLC) are expected in the first quarter of 2025. |
proactiveinvestors.com |
2025-01-13 11:21:28 |
Czytaj oryginał (ang.) |
| Candel Therapeutics Provides Corporate Update and Highlights Strong Pipeline Momentum and Key Value Drivers for 2025 |
NEEDHAM, Mass., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today highlighted recent successes across the Company's viral immunotherapy portfolio and provided an update on the Company's cash position and upcoming 2025 milestones. |
globenewswire.com |
2025-01-13 10:00:00 |
Czytaj oryginał (ang.) |
| Best-Performing Stocks Of 2024 |
Best-Performing Stocks Of 2024 |
seekingalpha.com |
2025-01-03 01:46:00 |
Czytaj oryginał (ang.) |
| 2025 biotech outlook: Small-cap innovators tackling chronic and rare diseases |
In the New Year, many small-cap biotech companies will be advancing promising clinical trials with innovative therapies aimed at addressing significant unmet medical needs. Key trials include those focused on cancer immunotherapies, treatments for neurological conditions like multiple sclerosis and Alzheimer's, as well as novel approaches to metabolic diseases and chronic pain. |
proactiveinvestors.com |
2024-12-23 16:41:31 |
Czytaj oryginał (ang.) |
| Candel Therapeutics rides high on promising Phase 3 data, funding boost |
Candel Therapeutics Inc (NASDAQ:CADL) shares skyrocketed by nearly 43% on Thursday following a string of positive news surrounding the company's cancer drug pipeline. Last week the Needham, Massachusetts-based company released promising results from its Phase 3 clinical trial for CAN-2409, its experimental immunotherapy for localized prostate cancer. |
proactiveinvestors.com |
2024-12-19 17:16:19 |
Czytaj oryginał (ang.) |
| Candel Therapeutics raises $92M in public offering following prostate cancer trial success |
Candel Therapeutics Inc (NASDAQ:CADL) announced on Monday the completion of a public offering that raised approximately $92 million in gross proceeds. The offering included 12 million shares of common stock at $6 per share and pre-funded warrants for 3.3 million shares at $5.99 per warrant, allowing buyers to acquire shares at an exercise price of $0.01 each. |
proactiveinvestors.com |
2024-12-16 18:26:08 |
Czytaj oryginał (ang.) |
| Candel Therapeutics Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares |
NEEDHAM, Mass., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (“Candel”) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced the closing of its previously announced underwritten public offering of 12,000,001 shares of its common stock at a price to the public of $6.00 per share and pre-funded warrants to purchase up to an aggregate of 3,333,333 shares of its common stock at a price to the public of $5.99 per pre-funded warrant to purchase one share of the common stock, which represents the per share public offering price for the common stock less the $0.01 per share exercise price for each such pre-funded warrant. The 12,000,001 shares of common stock sold in the offering include 2,000,000 shares sold pursuant to the full exercise of the underwriters' option to purchase up to 2,000,000 additional shares of common stock at the public offering price, less the underwriting discount. |
globenewswire.com |
2024-12-16 18:01:00 |
Czytaj oryginał (ang.) |
| Candel Therapeutics, 8x8 And Other Big Stocks Moving Lower In Friday's Pre-Market Session |
U.S. stock futures were higher this morning, with the Nasdaq futures gaining around 150 points on Friday. |
benzinga.com |
2024-12-13 10:53:42 |
Czytaj oryginał (ang.) |
| Candel Therapeutics unveils $80M public offering |
Candel Therapeutics Inc (NASDAQ:CADL) has announced an $80 million underwritten public offering of its common stock and pre-funded warrants. The offering includes approximately 10 million shares of common stock at $6 per share and approximately 3.33 million pre-funded warrants priced at $5.99 each, representing the public offering price minus a $0.01 per share exercise cost. |
proactiveinvestors.com |
2024-12-13 10:48:57 |
Czytaj oryginał (ang.) |
| Candel Therapeutics Announces Pricing of Public Offering |
NEEDHAM, Mass., Dec. 12, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (“Candel”) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced the pricing of an underwritten public offering of 10,000,001 shares of its common stock at a price to the public of $6.00 per share and pre-funded warrants to purchase up to an aggregate of 3,333,333 shares of its common stock at a price to the public of $5.99 per pre-funded warrant to purchase one share of the common stock, which represents the per share public offering price for the common stock less the $0.01 per share exercise price for each such pre-funded warrant. The gross proceeds from the offering to Candel are expected to be approximately $80 million, before deducting underwriting discounts and commissions and other offering expenses. The offering is expected to close on or about December 16, 2024, subject to customary closing conditions. In addition, Candel has granted the underwriters a 30-day option to purchase up to 2,000,000 additional shares of common stock at the public offering price, less the underwriting discount. |
globenewswire.com |
2024-12-13 01:00:00 |
Czytaj oryginał (ang.) |
| Candel Therapeutics Announces $80 Million Proposed Public Offering |
NEEDHAM, Mass., Dec. 12, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (“Candel”) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced the launch of an underwritten public offering of $80 million of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock. All shares of common stock and pre-funded warrants to be sold in the offering will be offered by Candel. Candel also intends to grant the underwriters a 30-day option to purchase up to an additional $12 million of the shares of its common stock offered in the public offering under the same terms and conditions. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering. |
globenewswire.com |
2024-12-12 18:51:00 |
Czytaj oryginał (ang.) |
| CADL Stock Soars as Phase III Prostate Cancer Study Meets Primary Goal |
Candel stock rallies 68% on meeting the primary goal in a phase III study of CAN-2409 combo therapy compared to SOC radiation therapy for prostate cancer. |
zacks.com |
2024-12-12 13:36:09 |
Czytaj oryginał (ang.) |
| Candel Therapeutics: Surprising Win Puts Potential Drug Approval In Sight |
Candel's phase 3 trial for CAN-2409 in high-risk prostate cancer met its primary endpoint, showing a 14.5% improvement in disease-free survival over placebo. Financially, CADL holds $16.6 million in cash, facing a likely equity raise soon due to high operational expenses and limited cash runway. Despite a phase 2b trial setback in lower-risk prostate cancer, the phase 3 success supports a potential FDA submission by mid-2025. |
seekingalpha.com |
2024-12-11 14:19:15 |
Czytaj oryginał (ang.) |
| Biotech Stock Hits 3-Year Highs on Trial Results |
Candel Therapeutics Inc (NASDAQ:CADL) is soaring today, up 164% at $12.17 at last glance and earlier hitting a three-year high of $14.60, after the biotech company's prostate cancer immunotherapy treatment, CAN-2409, met its goal in a late-stage study. |
schaeffersresearch.com |
2024-12-11 12:55:17 |
Czytaj oryginał (ang.) |
| Candel Therapeutics Stock Surges Over 100% - Here's Why |
On Wednesday, Candel Therapeutics, Inc. CADL announced results from a phase 3 trial of CAN-2409 viral immunotherapy in intermediate-to-high-risk, localized prostate cancer patients. |
benzinga.com |
2024-12-11 11:19:44 |
Czytaj oryginał (ang.) |
| Candel Skyrockets By Triple Digits On A Potential First-In-20-Years Cancer Drug |
Shares of Candel Therapeutics skyrocketed Wednesday after the biotech company's prostate cancer treatment succeeded in a Phase 3 study. The post Candel Skyrockets By Triple Digits On A Potential First-In-20-Years Cancer Drug appeared first on Investor's Business Daily. |
investors.com |
2024-12-11 11:17:56 |
Czytaj oryginał (ang.) |
| Candel Therapeutics reports positive Phase 3 results for CAN-2409 in localized prostate cancer |
Candel Therapeutics Inc (NASDAQ:CADL) announced that its experimental immunotherapy, CAN-2409, met its main goal in a Phase 3 trial, significantly improving disease-free survival in patients with localized prostate cancer. The trial showed a 14.5% improvement in disease-free survival (DFS) at 54 months for the CAN-2409 group compared to the control arm and significantly reduced recurrence risk while improving prostate cancer-free survival. |
proactiveinvestors.com |
2024-12-11 10:52:56 |
Czytaj oryginał (ang.) |
| Candel Therapeutics' cancer drug meets late-stage trial goals |
Candel Therapeutics said on Wednesday its experimental prostate cancer drug met the main goal of a late-stage trial, sending the company's shares up 64% in premarket trading. |
reuters.com |
2024-12-11 09:09:50 |
Czytaj oryginał (ang.) |
| Candel Therapeutics Announces CAN-2409 Achieved Primary Endpoint in Phase 3 Prostate Cancer Trial, Showing Significantly Improved Disease-Free Survival |
NEEDHAM, Mass., Dec. 11, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced results from a multicenter phase 3 clinical trial evaluating CAN-2409 viral immunotherapy in localized prostate cancer patients. |
globenewswire.com |
2024-12-11 09:00:00 |
Czytaj oryginał (ang.) |
| Candel Therapeutics is pushing for a paradigm shift in cancer treatment |
Cancer treatment has long been dominated by traditional approaches such as surgery, radiation, and chemotherapy. But in recent years, a wave of innovation has emerged, driven by the promise of immunotherapies that harness the body's own immune system to fight cancer. |
proactiveinvestors.com |
2024-11-29 12:31:38 |
Czytaj oryginał (ang.) |
| Candel Therapeutics CEO: Putting patients first is the key to reframing cancer treatment |
In the biopharmaceutical world, where innovation and breakthroughs often dominate headlines, a fundamental question is frequently overlooked: are we truly listening to patients? For Paul Peter Tak CEO of Candel Therapeutics Inc (NASDAQ:CADL), the answer has shaped a career rooted in both scientific discovery and personal resilience. |
proactiveinvestors.com |
2024-11-22 12:01:26 |
Czytaj oryginał (ang.) |
| Candel Therapeutics CEO anticipates 'paradigm shift' in prostate cancer treatment as Q3 work wraps up |
Candel Therapeutics Inc (NASDAQ:CADL) CEO Paul Peter Tak expressed optimism for a "paradigm shift" in prostate cancer treatment as the biopharmaceutical company moves closer to phase 2b and phase 3 trial data releases for its lead therapy, CAN-2409. Tak stated the data, expected in the fourth quarter of 2024, could pave the way for new regulatory approvals for CAN-2409 in non-metastatic, localized prostate cancer. |
proactiveinvestors.com |
2024-11-14 11:44:22 |
Czytaj oryginał (ang.) |